LeaderMed is a global, innovative biopharmaceutical company that leverages the Asia-Pacific market, expediting R&D cost-effectively; In addition to penetrating the APAC market and bringing significant sales, we generate quality clinical data that can be used by partners to initiate Phase 3 or pivotal trials elsewhere, such as the U.S. and EMEA; LeaderMed is developing first-in-class therapeutics in several diseases with significant unmet needs. The current company pipeline includes therapeutic candidates for: diabetes, obesity, hemophilia A and B, lung fibrosis, myocardial fibrosis, and scar-less wound healing. Headquartered in the U.S. and with operations and manufacturing capabilities in Korea, Singapore and China, LeaderMed is led by a veteran executive team featuring decades of collective expertise in the full lifecycle of drug development.